Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Aurinia Pharmaceuticals (AUPH) Share Price
Headlines about Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aurinia Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.4141910373968 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Several research firms have recently commented on AUPH. Vetr lowered Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating and set a $6.64 target price for the company. in a report on Wednesday, September 6th. Seaport Global Securities reaffirmed a “buy” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a report on Friday, October 6th. BidaskClub lowered Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Zacks Investment Research raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a report on Tuesday, August 15th. Finally, Cantor Fitzgerald set a $14.00 target price on Aurinia Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 11th. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has given a strong buy rating to the company. Aurinia Pharmaceuticals presently has an average rating of “Buy” and an average price target of $9.82.
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) traded up 1.618% during trading on Thursday, reaching $6.595. The company had a trading volume of 720,171 shares. The company’s market cap is $550.58 million. The firm has a 50-day moving average of $6.34 and a 200-day moving average of $6.55. Aurinia Pharmaceuticals has a 12-month low of $2.02 and a 12-month high of $10.54.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.10. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. The business had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.06 million. On average, equities research analysts anticipate that Aurinia Pharmaceuticals will post ($1.01) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This news story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/12/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-aurinia-pharmaceuticals-auph-share-price.html.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Stock Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.